Aopecia Areata – PharmaLive

Eli Lilly says FDA could deny expanded use of arthritis drug for eczema

AbbVie, Aopecia Areata, Arthritis, Blockbusters, Clinical Trials, Eczema, Eli Lilly, FDA, Hair Loss, Hospitalized COVID-19 Patients, Janus Kinase (JAK) Inhibitors, New Indications, Pfizer, Priority Review Status, R&D, Rivalries, Therapeutics

Eli Lilly said on Jan. 28 the company expects the U.S. Food and Drug Administration to decline the approval of expanded use of the rheumatoid arthritis drug Olumiant as a treatment for adults with moderate-to-severe eczema.

FDA lifts hold on Concert Pharma’s hair loss study

Aopecia Areata, Autoimmune Disorders, Clinical Hold, FDA, FDA/Regulatory, Hair Loss

The U.S. FDA lifted a clinical hold on a trial testing Concert Pharmaceuticals Inc.’s therapy for alopecia areata, a type of hair loss.

FDA clinical hold on Concert’s hair loss drug

Aopecia Areata, Clinical Hold, FDA, FDA/Regulatory, Hair Loss

Concert Pharmaceuticals Inc. said the U.S. FDA imposed a clinical hold on a trial testing the company’s drug to treat alopecia areata, a type of hair loss.